|

CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc） Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Tianjin Medical University General Hospital1

Indications

  • T-lymphocyte Lymphoma1
  • T-ALL/Lymphoma1
  • Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)1
  • B-ALL1
  • Myeloma, Multiple1

Other1 trial

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.